REG - BkofA Merrill Lynch Horizon Therapeutics - 20230112_HORIZON THERAPEUTICS PLC_38.5(b)_IE_BOFAS

AmgenAnnouncement

13/01/2023 12:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230113:nRSM7060Ma&default-theme=true

RNS Number : 7060M  Bank of America Merrill Lynch  13 January 2023

FORM 38.5(b)

 

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2013

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT

RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNIZED INTERMEDIARY

STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

 

 1.  KEY INFORMATION

 Name of exempt principal trader             BofA Securities, Inc.
 Company dealt in                            HORIZON THERAPEUTICS PLC
 Class of relevant security to which the     Common - IE00BQPVQZ61

dealings being disclosed relate(Note 1)
 Date of dealing                             12/01/2023

BofA Securities, Inc.

 Company dealt in

HORIZON THERAPEUTICS PLC

 Class of relevant security to which the

dealings being disclosed relate(Note 1)

Common - IE00BQPVQZ61

 Date of dealing

12/01/2023

 

 2.  INTERESTS AND SHORT POSITIONS

 (a)  Interests and short positions (following dealing) in the class of relevant
      security

dealt in (Note 2)

 Class of relevant security: Common             IE00BQPVQZ61
                                                Long             Short
                                                Number   %       Number  %
 (1)  Relevant securities                       254,499  0.112%  11,044  0.005 %
 (2)  Derivatives (other than options):         9,268    0.004%  25,034  0.011%
 (3)  Options and agreements to purchase/sell:  0        0%      100     0%
 Total                                          263,767  0.116%  36,178  0.016%

254,499

0.112%

11,044

0.005 %

 (2)  Derivatives (other than options):

9,268

0.004%

25,034

0.011%

 (3)  Options and agreements to purchase/sell:

0

0%

100

0%

Total

263,767

0.116%

36,178

0.016%

 

 (b)  Interests and short positions in relevant securities of the company, other
      than the

class dealt in (Note 2)

 Class of relevant security:
                                                Long         Short
                                                Number  %    Number  %
 (1)  Relevant securities                       0       0%   0       0%
 (2)  Derivatives (other than options):         0       0%   0       0%
 (3)  Options and agreements to purchase/sell:  0       0%   0       0%
 Total                                          0       0%   0       0%

0

0%

0

0%

 (2)  Derivatives (other than options):

0

0%

0

0%

 (3)  Options and agreements to purchase/sell:

0

0%

0

0%

Total

0

0%

0

0%

 3.  DEALINGS (Note 3)

 (a)  Purchases and sales

 

 Purchase/sale  Number of relevant securities  Price per unit (Note 4)
 Purchase               100                    113.173 USD
 Purchase               800                    113.175 USD
 Purchase            3,291                     113.18 USD
 Purchase                  1                   113.19 USD
 Purchase            2,300                     113.205 USD
 Purchase            2,851                     113.21 USD
 Purchase               400                    113.24 USD
 Purchase               400                    113.245 USD
 Purchase            8,477                     113.295 USD
 Purchase          36,532                      113.3 USD
 Purchase          30,318                      113.2 USD
 Purchase            2,282                     113.21 USD

 

 

 Purchase/sale  Number of relevant securities  Price per unit (Note 4)
 Sale                     16                   113.21 USD
 Sale              43,000                      113.17 USD
 Sale                     72                   113.21 USD

 

 (b)  Derivatives transactions (other than options transactions)

 Product name,  Nature of transaction        Number of relevant securities  Price per unit

e.g. CFD
(Note 5)                    (Note 6)
(Note 4)
 Swap           Increasing a short position  80                             113.21 USD

 

 (c)  Options transactions in respect of existing relevant securities

 (i)  Writing, selling, purchasing or varying

 Product name, e.g. call option  Writing, selling, purchasing, varying etc.  Number of securities to which the option relates (Note 7)  Exercise price  Type, e.g. American, European etc  Expiry date  Option money paid/ received per unit (Note 4)
 N/A                             N/A                                         N/A                                                        N/A             N/A                                N/A          N/A

 

 (ii)  Exercising

 Product name,      Number of securities  Exercise price per

e.g. call option
unit (Note 4)
 N/A                N/A                   N/A

 

 (d)  Other dealings (including transactions in respect of new securities) (Note 3)

 Nature or transaction  Details  Price per unit
 (Note 7)
(if applicable) (Note 4)

 N/A                    N/A      N/A

 

 4.  OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 Full details of any agreement, arrangement or understanding between the person

disclosing and any other person relating to the voting rights of any relevant

securities under any option referred to on this form or relating to the voting
 rights

or future acquisition or disposal of any relevant securities to which any
 derivative

referred to on this form is referenced. If none, this should be stated.
 None

 

 Is a Supplemental Form 38.5(b) attached? (Note 8)  No

 

 Date of disclosure                            13/01/2023
 Contact name                                  Frank Lui
 Telephone number                              +44207 995 0334
 Name of offeree/offeror with which connected  AMGEN INC
 Nature of connection (Note 9)                 Advisor to - AMGEN INC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ISEEAFFDFLDDEFA